The paradoxical development of cutaneous squamous cell carcinoma and keratoacanthoma in patients with malignant melanoma treated with a BRAF-inhibitor

The treatment of metastasized or inoperable melanoma with the BRAF-inhibitors vemurafenib and dabrafenib is accompanied by a lot of cutaneous side effects. By a paradoxical activation of the MAPK-pathway malignant keratinocyte proliferation may occur with the appearance of cutaneous squamous cell carcinoma and keratoacanthomas. Early diagnosis and adequate approach can prevent dose reduction or discontinuation of the BRAFinhibitor. Regular inspection of the skin by a dermatologist and the association of MEKinhibitors are important. The use of acitretin and COX-2 inhibitors are alternative preventive options.

Jaar van publicatie:2017